EYPT vs OTLK
EYPT: EyePoint Pharmaceuticals is a clinical-stage biopharma developing sustained-release treatments for retinal diseases including wet AMD and diabetic macular edema, with the approved product DEXYCU generating minimal revenue. OTLK: Outlook Therapeutics develops ophthalmic biologics for retinal diseases, with its lead product LYTENAVA (bevacizumab gamma) approved in Europe and under FDA review in the US for wet AMD treatment.
Side-by-side fundamentals
| Metric | EYPT | OTLK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $12.41 | $1.07 | |
| Market cap as of 2026-07-30 | $1.0B | $187M | |
| PEG as of 2026-07-30 | -0.08 | n/a | |
| Net margin as of 2026-07-30 | -3566.6% | -1507.0% | OTLK higher |
| Gross margin as of 2026-07-30 | +76.5% | +4.0% | EYPT higher |
| Operating margin as of 2026-07-30 | -3700.9% | -1806.2% | OTLK higher |
| ROE as of 2026-07-30 | -110.5% | -415.5% | EYPT higher |
| ROA as of 2026-07-30 | -90.1% | -300.6% | EYPT higher |
| Debt / equity as of 2026-07-30 | 0.00 | 3.04 | EYPT lower |
| Revenue growth (YoY) as of 2026-07-30 | -86.4% | -22.9% | OTLK higher |
| Revenue CAGR (3y) SEC XBRL | -8.8% | n/a | |
| Beta as of 2026-07-30 | 1.68 | 0.80 | |
| 1-year return as of 2026-07-27 close | +18.4% | -47.8% | EYPT higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.